Relatively, M344 may be a poor inhibitor of HDAC11 (18% inhibition at 100 μΜ in HEK293) in comparison to vorinostat, which significantly upregulated HDAC11-target genes in breast cancer cells at 0.5 μΜ [29,44]. The gene discussed is HDAC11; the disease is breast carcinoma.